JPS63211232A - Hemostatic agent - Google Patents
Hemostatic agentInfo
- Publication number
- JPS63211232A JPS63211232A JP4614287A JP4614287A JPS63211232A JP S63211232 A JPS63211232 A JP S63211232A JP 4614287 A JP4614287 A JP 4614287A JP 4614287 A JP4614287 A JP 4614287A JP S63211232 A JPS63211232 A JP S63211232A
- Authority
- JP
- Japan
- Prior art keywords
- chitin
- hydrochloride
- hemostatic agent
- derivative
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940030225 antihemorrhagics Drugs 0.000 title claims abstract description 23
- 239000002874 hemostatic agent Substances 0.000 title claims abstract description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229920002101 Chitin Polymers 0.000 claims abstract description 44
- 206010052428 Wound Diseases 0.000 abstract description 13
- 208000027418 Wounds and injury Diseases 0.000 abstract description 13
- 239000000835 fiber Substances 0.000 abstract description 12
- 239000000843 powder Substances 0.000 abstract description 10
- 239000002552 dosage form Substances 0.000 abstract description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract description 6
- 238000010306 acid treatment Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 abstract description 3
- 239000003513 alkali Substances 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 abstract description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 3
- 241000238424 Crustacea Species 0.000 abstract description 2
- 241000238631 Hexapoda Species 0.000 abstract description 2
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 abstract description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 abstract description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 abstract 1
- 238000007796 conventional method Methods 0.000 abstract 1
- 230000000850 deacetylating effect Effects 0.000 abstract 1
- 230000002008 hemorrhagic effect Effects 0.000 abstract 1
- 235000011121 sodium hydroxide Nutrition 0.000 abstract 1
- 235000010215 titanium dioxide Nutrition 0.000 abstract 1
- 208000032843 Hemorrhage Diseases 0.000 description 17
- 230000000740 bleeding effect Effects 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920001661 Chitosan Polymers 0.000 description 6
- 229920000742 Cotton Polymers 0.000 description 6
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002439 hemostatic effect Effects 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920002201 Oxidized cellulose Polymers 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229960002319 barbital Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 229940107304 oxidized cellulose Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- NSVFSAJIGAJDMR-UHFFFAOYSA-N 2-[benzyl(phenyl)amino]ethyl 5-(5,5-dimethyl-2-oxido-1,3,2-dioxaphosphinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate Chemical compound CC=1NC(C)=C(C(=O)OCCN(CC=2C=CC=CC=2)C=2C=CC=CC=2)C(C=2C=C(C=CC=2)[N+]([O-])=O)C=1P1(=O)OCC(C)(C)CO1 NSVFSAJIGAJDMR-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 239000005714 Chitosan hydrochloride Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229950003102 efonidipine Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、止血剤に関するものであり、さらに詳しくは
特に外科手術等における切開創、切除創などの出血部に
おける止血に有効な止血剤に関するものである。DETAILED DESCRIPTION OF THE INVENTION (Field of Industrial Application) The present invention relates to a hemostatic agent, and more particularly to a hemostatic agent effective for stopping bleeding at bleeding sites such as incisions and excision wounds in surgical operations. It is something.
（従来の技術）（発明が解決しようとする問題点）従来
、外科手術等の出血を止血するものとして。(Prior Art) (Problems to be Solved by the Invention) Conventionally, it has been used to stop bleeding during surgical operations, etc.
薬剤を中心にして多くのものが商品として使用されてい
る。その中で、物理的圧迫による止血及び凝血を促進す
る化学的な止血作用の両者を利用するタイプの止血剤と
して１例えば、ゼラチンスポンジ（商品名：スポンゼル
、山内製薬）、酸化セルローズ綿（商品名ニオキシセル
、三共製薬）。Many things are used as commercial products, mainly medicines. Among them, hemostatic agents that utilize both physical pressure to stop hemorrhage and chemical hemostasis that promotes blood clotting include gelatin sponge (product name: Sponzel, Yamauchi Pharmaceutical), oxidized cellulose cotton (product name). Nioxycel, Sankyo Pharmaceutical).
コラーゲンの塩酸塩（商品名：アビテン、ゼリア薬品）
があげられる。これらは特に吻合、結紮が困難な場所に
対して使用されているが、短時間で。Collagen hydrochloride (product name: Aviten, Zeria Pharmaceutical)
can be given. These are especially used for anastomoses, places where ligation is difficult, but in a short time.
完全に、かつ処置後に再出血がおこらないよう安全に止
血を行うという点では、必ずしも満足できるものではな
い。It is not always satisfactory in terms of completely and safely stopping bleeding to prevent re-bleeding after the procedure.
また、特開昭５９−８８４２４号公報により。Also, according to Japanese Patent Application Laid-Open No. 59-88424.
キチンの脱アセチル化物であるキトサンに止血作用のあ
ることが知られている。Chitosan, a deacetylated product of chitin, is known to have a hemostatic effect.
しかしながら、キトサンは、いかなる剤型で使用しても
、止血剤における止血効果としては、長時間に及ぶマイ
ルドな止血には効果があがるものの、急を嬰する手術等
において迅速な止血を行うには必ずしも充分なものでは
ない。However, no matter what form chitosan is used in, it is effective for mild hemostasis over a long period of time as a hemostatic agent; It's not necessarily sufficient.
本発明の目的は、迅速で、完全に、かつ安全な止血を行
うことができる止血剤を提供することにある。An object of the present invention is to provide a hemostatic agent capable of performing rapid, complete, and safe hemostasis.
（問題点を解決するための手段）
本発明者らは、上記の問題点を解決するために鋭意研究
を重ねた結果、キチンの塩酸塩又はキチン誘導体の塩酸
塩が止血剤として良好な性能を有することを見出し１本
発明に到達したものである。(Means for Solving the Problems) As a result of extensive research to solve the above problems, the present inventors have found that chitin hydrochloride or chitin derivative hydrochloride has good performance as a hemostatic agent. The present invention was achieved by discovering that the present invention has the following properties.
すなわち２本発明は、キチンの塩酸塩又はキチン誘導体
の塩酸塩からなる止血剤を要旨とするものである。That is, the gist of the present invention is a hemostatic agent comprising a hydrochloride of chitin or a hydrochloride of a chitin derivative.
本発明でキチンとは、甲殻類、昆虫類の外骨格等を、塩
酸処理等の酸処理ならびに力性ソーダ処理等のアルカリ
処理を行って、タン白及びカルシウム分を分離精製する
ことによって得られるポリ−Ｎ−アセチル−Ｄ−グルコ
サミンを主体とした精製物をいう。また、キチン誘導体
とは、このキチンのアセチルアミノ基の一部又は全部が
脱アセチル化された。いわゆる脱アセチルキチン又はキ
トサン、及びキチンのＯＨ又はＣｌＩ２０Ｈ５を例えば
、エーテル化、エステル化、カルギキシメチル化、ヒド
ロキシエチル化、０−エチル化したものを意味するが１
本発明においては、精製された天然のキチンを、所望の
剤型とした後、１５〜４０重匿％の力性ソーダ水溶液を
用いて８０〜１２０℃で３０分〜５時間処理することに
よって脱アセチル化したものが好ましく用いられる。In the present invention, chitin is obtained by subjecting the exoskeleton of crustaceans and insects to acid treatment such as hydrochloric acid treatment and alkali treatment such as hydrochloric acid treatment to separate and purify protein and calcium components. It refers to a purified product mainly consisting of poly-N-acetyl-D-glucosamine. Moreover, a chitin derivative is one in which part or all of the acetylamino groups of this chitin have been deacetylated. It means so-called deacetylated chitin or chitosan, and chitin OH or ClI20H5, for example, etherified, esterified, cargyxymethylated, hydroxyethylated, or 0-ethylated.1
In the present invention, purified natural chitin is made into a desired dosage form, and then treated with an aqueous solution of 15 to 40% sodium bicarbonate at 80 to 120°C for 30 minutes to 5 hours to remove the Acetylated ones are preferably used.
キチンの塩酸塩又はキチン誘導体の塩酸塩とは。What is chitin hydrochloride or chitin derivative hydrochloride?
これらのキチン又はキチン誘導体、好ましくは。These chitin or chitin derivatives, preferably.
脱アセチル化されたものの塩酸塩を意味する。塩酸塩は
、キチン又はキチン誘導体を２例えば、０．５〜３Ｎの
塩酸等の希塩酸で処理したのち余分の塩酸を濾過によっ
て除去するか、又は塩化水素ガスに接触させた後、水や
アルコール類で洗浄し、さらに乾燥することによって１
作成することができる。Refers to the deacetylated hydrochloride. Hydrochloride can be obtained by treating chitin or a chitin derivative with dilute hydrochloric acid such as 0.5 to 3N hydrochloric acid, removing excess hydrochloric acid by filtration, or contacting it with hydrogen chloride gas, and then treating it with water or alcohol. 1 by washing with water and drying
can be created.
本発明において好ましいキチンの塩酸塩又はキチン誘導
体の塩酸塩は、その０．３ｇを２５℃の水４０ＣＣの中
に入れ、攪拌してから測定したときのｐ １）が４．５
以下、とくに２．５〜４．０のものである。In the present invention, preferred chitin hydrochloride or chitin derivative hydrochloride has a p1) of 4.5 when 0.3 g is poured into 40 cc of water at 25°C, stirred, and then measured.
In particular, the following values are from 2.5 to 4.0.
塩酸塩のｐ ＨＯ調性は、塩酸塩の製造時の余分の塩酸
の濾過方法、水やアルコール類での洗浄時間。The PHO tonality of hydrochloride is determined by the method of filtering excess hydrochloric acid during the production of hydrochloride, and the washing time with water or alcohol.
回数等を変えて、グルコサミン基と塩酸の結合量を変化
させることによって行うことができる。This can be carried out by changing the number of times etc. to change the amount of binding between glucosamine groups and hydrochloric acid.
上記のごときキチンの塩酸塩又はキチンＦａＨ！一体の
塩酸塩からなる本発明の止血剤は９例えば、外科術等の
切除部や切開部等に発生する出血部に装着可能な、粉末
、繊維、フィブリル、スポンジ。The above chitin hydrochloride or chitin FaH! The hemostatic agent of the present invention, which is composed of an integral hydrochloride salt, can be used in the form of a powder, fiber, fibril, or sponge, which can be applied to a bleeding site that occurs at a resection or incision site, for example, in a surgical procedure.
フルム等の剤型であることが好ましいが、とくに粉末、
繊維、フィブリルが好ましく、繊゛維としては太さが１
０デニール以下で、長さが１０ｃｍ以下の短繊維状のも
のが好ましい。これらの剤型の止血剤を作成するために
は、まず、キチン又はキチン誘導体の粉末を塩酸塩にし
た後に溶剤に溶解して２所望の剤型としてもよいし、あ
るいはキチン又はキチン誘導体を溶剤に溶解して得たド
ープを凝固して所望の剤型とした後、塩酸塩としてもよ
い。It is preferable to use a dosage form such as flume, but especially powder,
Fibers and fibrils are preferred, and the fibers have a thickness of 1
Short fibers with a denier of 0 denier or less and a length of 10 cm or less are preferred. In order to create these dosage forms of hemostatic agents, the powder of chitin or chitin derivatives may first be made into a hydrochloride salt and then dissolved in a solvent to form the desired dosage form, or chitin or chitin derivatives may be dissolved in a solvent. After solidifying the dope obtained by dissolving it into a desired dosage form, it may be converted into a hydrochloride.
この際に使用する溶剤としては、アセチルグルコサミン
基の多いキチンの場合には１例えば、塩化リチウムを含
むＮ−メチルピロリドン又はジメチルアセトアミド溶液
や、トリクロル酢酸とハロゲン化炭化水素との混合溶液
が好ましく使用され。In the case of chitin with many acetylglucosamine groups, the solvent used in this case is preferably a solution of N-methylpyrrolidone or dimethylacetamide containing lithium chloride, or a mixed solution of trichloroacetic acid and a halogenated hydrocarbon. It is.
一方、グルコサミン基の多いキチン（一般にはキトサン
と呼称される。）の場合には、酢酸等の酸水溶液を好ま
しく使用することができる。これら溶液から、前記の種
々の剤型の止血剤を作成するには、それぞれの剤型を作
成する個別の方法によって行うことができる。例えば、
繊維を作成するには、キチンドープをステンレスネット
等で濾過して未溶解分や異物を除いた後、ギヤーポンプ
等で輸送、計量し、ノズルから水、メタノール、エタノ
ール、ブタノール等のアルコール類、アセトン等のケト
ン類等からなる凝固液中に押し出して凝固する。凝固し
た糸条は２例えば、廻転ローラー等で２〜５０ｍ／ｓｉ
ｎ程度の速度で引き取り。On the other hand, in the case of chitin (generally called chitosan) which has many glucosamine groups, an aqueous acid solution such as acetic acid can be preferably used. The various dosage forms of hemostatic agents described above can be prepared from these solutions by individual methods for producing each dosage form. for example,
To create fibers, the chitin dope is filtered through a stainless steel net to remove undissolved matter and foreign matter, then transported and weighed using a gear pump, and then passed through a nozzle to water, alcohols such as methanol, ethanol, butanol, acetone, etc. It is coagulated by extruding it into a coagulating liquid consisting of ketones, etc. The coagulated yarn is heated at 2 to 50 m/si using a rotating roller, etc.
Pick up at a speed of about n.
ワインダー等によって捲き取り、さらに洗浄を行って、
糸条中に含まれる溶剤を十分に除去した後。Wind it up with a winder, etc., and wash it further.
After sufficiently removing the solvent contained in the yarn.
乾燥すればよい。Just dry it.
得られた繊維から、その塩酸塩を作成するには前記の方
法によって行うことができる。The hydrochloride salt can be prepared from the obtained fiber by the method described above.
本発明の止血剤は、乾燥状態で出血部に付与すればよい
が、付与直後に、その上部から木綿ガーゼ等で数分間圧
迫すると、より良い効果を発揮する。The hemostatic agent of the present invention may be applied to the bleeding area in a dry state, but it will be more effective if it is compressed from above with cotton gauze or the like for several minutes immediately after application.
（実施例）
以下、実施例をあげて本発明をさらに具体的に説明する
。(Examples) Hereinafter, the present invention will be explained in more detail by giving examples.
実施例１．比較例１．２
キチンの粉末（片倉チツカリン製）を１００メツシユに
粉砕し、ｌＮ−ＨＣｌにて４℃で１時間処理し、さらに
３％ＮａＯＨ液中で３時間、９０℃で加熱処理し、再度
キチンの粉末中に含まれるカルシウム分及び蛋白質を除
去し、水洗を繰り返し乾燥した。得られたキチンは、塩
化リチウムを８重量％含むジメチルアセトアミド溶液に
０．２重量％の濃度になるように溶解した溶液の粘度が
３０℃において２５１センチボイズの値を示すものであ
った。このキチンを７重量％の塩化リチウムを含んだジ
メチルアセトアミド溶液に７重量％になるように溶解し
た。得られたドープは１４８０メツシユ金網で濾過し、
放置脱泡のうえ、タンクに入れ加圧下でギヤーポンプに
て輸送し、１０００ホールのノズルより吐出ｉｔｌ１ｇ
／ｗｉｎの割合で８０℃の熱水中に押出して凝固し、
ｌ Ｑ ｍ／ｗｉｎの速度でローラーに引き取った。Example 1. Comparative Example 1.2 Chitin powder (manufactured by Chitsukarin Katakura) was ground into 100 meshes, treated with 1N-HCl at 4°C for 1 hour, and further heat-treated in 3% NaOH solution at 90°C for 3 hours, Calcium and protein contained in the chitin powder were removed again, and the powder was repeatedly washed with water and dried. The obtained chitin was dissolved in a dimethylacetamide solution containing 8% by weight of lithium chloride to a concentration of 0.2% by weight, and the viscosity of the solution was 251 centivoise at 30°C. This chitin was dissolved at a concentration of 7% by weight in a dimethylacetamide solution containing 7% by weight of lithium chloride. The obtained dope was filtered through a 1480 mesh wire mesh,
After being left to defoam, it is placed in a tank and transported using a gear pump under pressure, and then it is discharged from a 1000-hole nozzle at 1 g of it.
/win extruded into hot water at 80°C to solidify,
It was taken up by rollers at a speed of l Q m/win.
得られた糸条を水で十分に洗浄したのち乾燥して１単糸
デニール０．７３デニール、強度３．０ｇ／ｄの繊維を
得た。得られた繊維を５１にカットし、２３重重量％
ａ ０１（水溶液にて１２０℃で１時間処理して中和を
行ったのち洗浄、乾燥を行って綿状物を得た。次いで。The obtained yarn was thoroughly washed with water and then dried to obtain a fiber having a denier of 0.73 denier per single yarn and a strength of 3.0 g/d. The obtained fiber was cut into 51 pieces and 23% by weight.
a 01 (treated with an aqueous solution at 120° C. for 1 hour to neutralize, washed and dried to obtain a flocculent material. Then).
この綿状物を２Ｎ−塩酸に浸漬し、約２０℃で３０分間
処理した。処理後、吸引式濾過ビンで繊維の周囲の余分
の塩酸を除去したのち、約２０℃のメタノールを用いて
３０分間の洗浄を２回繰り返した後、乾燥してキチン繊
維からなる止血剤を得た。This cotton material was immersed in 2N hydrochloric acid and treated at about 20°C for 30 minutes. After the treatment, excess hydrochloric acid around the fibers was removed using a suction filter bottle, and then washed twice for 30 minutes using methanol at about 20°C, and then dried to obtain a hemostatic agent made of chitin fibers. Ta.
このキチン繊維からなる止血剤０．３ｇを４０℃の水中
に投入して２５℃でｐＨを測定したところ２．９であっ
た。When 0.3 g of the hemostatic agent made of this chitin fiber was put into 40°C water and the pH was measured at 25°C, it was found to be 2.9.
上記のようにして得られた止血剤の効果を以下のように
して確認した。The effect of the hemostatic agent obtained as described above was confirmed as follows.
すなわち９体重５．８ｋｇの雑成犬にバルビタール薬に
て麻酔を行い、電気メスにて胸部を切開した後、肺臓を
取出した。肺臓の表面に手術用はさみでたて４龍×よこ
４ｃｍの３コの切除部を作成したところ、いずれも定常
的な出血をみた。これらの傷に対して、実施例１の止血
剤、実施例１において塩酸塩にする前の線状物、（比較
例１）、あるいは牛真皮をアルカリ処理することによっ
て得られた微線維状コラーゲンを塩酸塩としたもの（比
較例２）を、それぞれ約５Ｏｎ＋ｇ付与した後、その上
から木綿のガーゼで約２分間圧迫し、ついでガーゼを取
り除いたところ、実施例１のものを付与した傷あるいは
比較例２のものを付与した傷では出血が止っていたが、
比較例１のものを付与した傷では依然として出血が止っ
ていなかった。その後。Specifically, a 9-year-old adult dog weighing 5.8 kg was anesthetized with a barbital drug, the chest was incised with an electric scalpel, and the lungs were removed. Three incisions measuring 4 cm in length and 4 cm in width were made on the surface of the lung using surgical scissors, and steady bleeding was observed in all of them. For these wounds, the hemostatic agent of Example 1, the linear material in Example 1 before being converted into hydrochloride (Comparative Example 1), or the microfibrous collagen obtained by alkali treatment of bovine dermis. After applying about 5 On+g of hydrochloride (Comparative Example 2), pressure was applied on top of it for about 2 minutes with cotton gauze, and then the gauze was removed. Bleeding had stopped in the wound treated with Comparative Example 2, but
Bleeding still had not stopped in the wound to which Comparative Example 1 was applied. after that.
そのままの状態で約２０分間放置したところ、比較例２
のものを付与した傷かられずかな出血が始まり放置と共
に出血は激しくなった。これに対し。When left as it was for about 20 minutes, Comparative Example 2
A small amount of bleeding started from the wound where the object was applied, and the bleeding became more intense as it was left untreated. Against this.
実施例１のものを付与した傷は２０分後も完全な止血が
行われており、出血はみられなかった。Even after 20 minutes, complete hemostasis was observed in the wound to which the wound of Example 1 was applied, and no bleeding was observed.
実施例２．比較例３．４
０．２Ｍ酢酸水溶液に０．２重量％溶解したときの粘度
が２０℃で５４センチボイズであるキトサン粉末（共和
油脂！？りを十分に乾燥した後、この粉末を２０℃で、
濃塩酸中から発生する塩化水素ガス中に３０分間暴露し
た後、メタノールを用いた３０分間の洗浄を２回くり返
したのち、乾燥してキトサンの塩酸塩からなる止血剤を
得た。Example 2. Comparative Example 3.4 Chitosan powder having a viscosity of 54 centiboise at 20°C when dissolved at 0.2% by weight in a 0.2M acetic acid aqueous solution (Kyowa Yushi!) was thoroughly dried, and then this powder was dissolved at 20°C. ,
After being exposed to hydrogen chloride gas generated from concentrated hydrochloric acid for 30 minutes, the sample was washed twice with methanol for 30 minutes, and then dried to obtain a hemostatic agent made of chitosan hydrochloride.
この止血剤の効果の確認を体重６．４ｋｇの雑成犬を使
用して行った。まず、この雑成犬をバルビタール薬にて
麻酔した後、電気メスにて胸部を切開し、肝臓を取り出
した。The effectiveness of this hemostatic agent was confirmed using a mixed adult dog weighing 6.4 kg. First, this adult dog was anesthetized with barbital, the chest was incised using an electric scalpel, and the liver was removed.
手術用はさみにて肝臓の端部から、たて１ｃｍ。Using surgical scissors, cut 1 cm vertically from the edge of the liver.
よこ２ｃｍ、厚み１龍の大きさの小片を３個切除したと
ころ、切除部からそれぞれ出血をみた。それぞれの切除
部に実施例２の止血剤、実施例２において塩酸塩にする
前のキトサン粉末（比較例３）。When three small pieces, each 2 cm wide and 1 dragon in thickness, were removed, bleeding was observed from each of the cut sites. The hemostatic agent of Example 2 was applied to each resection site, and the chitosan powder before being converted into hydrochloride in Example 2 (Comparative Example 3).
あるいは酸化セルローズ綿（比較例４）を約３０１ｍｇ
付与した後、その上部から木綿ガーゼで約２分間圧迫し
、ついでガーゼを取り除（と、実施例２のものを付与し
た傷あるいは比較例４のものを付与した傷は、出血して
いなかったのに対し、比較例３のものを付与した傷は全
体から出血が続いていた。そのまま３０分間放置したと
ころ、実施例２のものを付与した傷は止血したままであ
ったが。Or about 301 mg of oxidized cellulose cotton (Comparative Example 4)
After application, pressure was applied to the upper part of the wound for about 2 minutes with cotton gauze, and then the gauze was removed. On the other hand, the wound to which Comparative Example 3 was applied continued to bleed all over. When the wound was left as it was for 30 minutes, the wound to which Example 2 was applied remained stopped bleeding.
比較例４のものを付与した傷からは再び出血がはじまっ
た。Bleeding started again from the wound to which Comparative Example 4 was applied.
（発明の効果）
本発明の止血剤は、外科手術等における止血剤に対して
優れた止血効果を発揮するものであり。(Effects of the Invention) The hemostatic agent of the present invention exhibits an excellent hemostatic effect compared to hemostatic agents used in surgical operations and the like.
特に止血効果、使用性において優れているものである。It is particularly excellent in hemostatic effect and usability.
Claims (1)
る止血剤。(1) A hemostatic agent consisting of chitin hydrochloride or chitin derivative hydrochloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4614287A JPH0813746B2 (en) | 1987-02-27 | 1987-02-27 | Hemostatic agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4614287A JPH0813746B2 (en) | 1987-02-27 | 1987-02-27 | Hemostatic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63211232A true JPS63211232A (en) | 1988-09-02 |
| JPH0813746B2 JPH0813746B2 (en) | 1996-02-14 |
Family
ID=12738720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4614287A Expired - Lifetime JPH0813746B2 (en) | 1987-02-27 | 1987-02-27 | Hemostatic agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0813746B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09169653A (en) * | 1995-12-22 | 1997-06-30 | Unitika Ltd | Chitin-based hemostatic agent |
| JPH09169654A (en) * | 1995-12-22 | 1997-06-30 | Unitika Ltd | Hemostatic agent |
| JP2004526705A (en) * | 2001-02-12 | 2004-09-02 | マリン ポリマー テクノロジーズ，インコーポレーテッド | Compositions and methods for modulation of vasculature and / or function |
| JP2010024146A (en) * | 2008-07-15 | 2010-02-04 | Unitika Ltd | Hemostat |
-
1987
- 1987-02-27 JP JP4614287A patent/JPH0813746B2/en not_active Expired - Lifetime
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09169653A (en) * | 1995-12-22 | 1997-06-30 | Unitika Ltd | Chitin-based hemostatic agent |
| JPH09169654A (en) * | 1995-12-22 | 1997-06-30 | Unitika Ltd | Hemostatic agent |
| JP2004526705A (en) * | 2001-02-12 | 2004-09-02 | マリン ポリマー テクノロジーズ，インコーポレーテッド | Compositions and methods for modulation of vasculature and / or function |
| US8481512B2 (en) | 2001-02-12 | 2013-07-09 | Marine Polymer Technologies, Inc. | Compositions and methods for modulation of vascular structure and/or function |
| US8859528B2 (en) | 2001-02-12 | 2014-10-14 | Marine Polymer Technologies, Inc. | Compositions and methods for modulation of vascular structure and/or function |
| JP2016053067A (en) * | 2001-02-12 | 2016-04-14 | マリン ポリマー テクノロジーズ，インコーポレーテッド | Compositions and methods for modulation of vascular structure and/or function |
| JP2010024146A (en) * | 2008-07-15 | 2010-02-04 | Unitika Ltd | Hemostat |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0813746B2 (en) | 1996-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4405324A (en) | Absorbent cellulosic structures | |
| US4543410A (en) | Absorbent cellulosic base structures | |
| US4651725A (en) | Wound dressing | |
| EP0075791A1 (en) | Absorbent wound dressing and processes for its production | |
| CN109498833A (en) | A kind of Medical absorbable polysaccharide composite material and application thereof | |
| JPS6059123A (en) | Production of chitosan fiber | |
| JPH02124903A (en) | Dispersion of and product from chitin | |
| JPS6250498B2 (en) | ||
| JPS63211232A (en) | Hemostatic agent | |
| CH627078A5 (en) | Process for the preparation of a sterile collagen product with felt-like or web-like fibre structure | |
| JPH04371161A (en) | Web of chitin | |
| JPH10337302A (en) | Tympanic membrane absence closure promoting material and manufacture thereof | |
| JP2754162B2 (en) | Manufacturing method of chitin sponge, chitin paper and chitin film | |
| CN105568675B (en) | A kind of preparation method of H-type carboxymethyl chitosan fiber | |
| JPH0442019B2 (en) | ||
| CN106421886A (en) | Hydrogel dressing for repairing wounds and preparation method of hydrogel dressing | |
| JPH09169654A (en) | Hemostatic agent | |
| JPS6261603B2 (en) | ||
| JPH0551401A (en) | Antibacterial agent-containing chitin form | |
| JPS6164256A (en) | Wound covering protective material | |
| JPH09169653A (en) | Chitin-based hemostatic agent | |
| JP3546367B2 (en) | Method for producing water-soluble alginate fiber | |
| JPH1075998A (en) | Cotton-like wound protective material | |
| JPS62170254A (en) | Wound covering protective material | |
| CN117586426A (en) | Oxidized regenerated cellulose and preparation method and application thereof |